Logo image of CMTA

CLEMENTIA PHARMACEUTICALS INC (CMTA) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:CMTA -

26.35
-0.03 (-0.11%)
Last: 4/17/2019, 8:00:00 PM
26.05
-0.3 (-1.14%)
After Hours: 4/17/2019, 8:00:00 PM

CMTA Key Statistics, Chart & Performance

Key Statistics
Market Cap1.00B
Revenue(TTM)N/A
Net Income(TTM)-58.13M
Shares38.06M
Float19.15M
52 Week High26.73
52 Week Low8.1
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-1.59
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
CMTA short term performance overview.The bars show the price performance of CMTA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150

CMTA long term performance overview.The bars show the price performance of CMTA in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40

The current stock price of CMTA is 26.35 null. In the past month the price increased by 1.78%. In the past year, price increased by 49.46%.

CLEMENTIA PHARMACEUTICALS INC / CMTA Daily stock chart

CMTA Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to CMTA. When comparing the yearly performance of all stocks, CMTA is one of the better performing stocks in the market, outperforming 98.07% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CMTA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to CMTA. CMTA has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CMTA Financial Highlights

Over the last trailing twelve months CMTA reported a non-GAAP Earnings per Share(EPS) of -1.5899999999999999. The EPS increased by 77.59% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -32.87%
ROE -35.35%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%74.86%
Sales Q2Q%N/A
EPS 1Y (TTM)77.59%
Revenue 1Y (TTM)N/A

CMTA Forecast & Estimates


Analysts
Analysts60
Price TargetN/A
EPS Next Y79.45%
Revenue Next YearN/A

CMTA Ownership

Ownership
Inst Owners78.72%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About CMTA

Company Profile

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company's lead product consists of palovarotene, a novel RAR' agonist, to treat fibrodysplasia ossificans progressiva, multiple osteochondroma and other diseases. Clementia Pharmaceuticals Inc. is based in Montreal, Canada.

Company Info

CLEMENTIA PHARMACEUTICALS INC

4150 ST CATHERINE STREET WEST SUITE 550

MONTREAL A8 H3Z 2Y5

CEO: Clarissa Desjardins

Phone: 514-940-3600

CLEMENTIA PHARMACEUTICALS INC / CMTA FAQ

What does CLEMENTIA PHARMACEUTICALS INC do?

Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company's lead product consists of palovarotene, a novel RAR' agonist, to treat fibrodysplasia ossificans progressiva, multiple osteochondroma and other diseases. Clementia Pharmaceuticals Inc. is based in Montreal, Canada.


Can you provide the latest stock price for CLEMENTIA PHARMACEUTICALS INC?

The current stock price of CMTA is 26.35 null. The price decreased by -0.11% in the last trading session.


Does CLEMENTIA PHARMACEUTICALS INC pay dividends?

CMTA does not pay a dividend.


What is the ChartMill technical and fundamental rating of CMTA stock?

CMTA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.